Arcus Q2 revenue rises to $160 million on one-time $143 million catch-up
Arcus Biosciences reported second-quarter 2025 revenue of $160 million, up from $39 million a year earlier, and broke even on a net basis after a $93 million net loss in the same quarter of 2024. Most of the revenue increase came from a $143 million cumulative catch-up tied to pausing etrumadenant development and Gilead returning its license, so shareholders should weigh that one-time item against the six-month net loss, which widened to $112 million from $97 million.
Key points
- Q2 2025 total revenue was $160 million versus $39 million in Q2 2024, including a $143 million cumulative catch-up tied to etrumadenant.
- Cash, cash equivalents and marketable securities were $927 million at June 30, 2025, compared with $992 million at December 31, 2024.
- Arcus expects full-year 2025 GAAP revenue of $225 million to $235 million and expects R&D expenses to decline starting in Q4 2025.
The filing
Written by AI on Nov 8, 2026, 1:49 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.